| Trial ID: | L2038 |
| Source ID: | NCT05305794
|
| Associated Drug: |
Insulin + Semaglutide Treatment
|
| Title: |
Effect of Weekly GLP1 Agonist Treatment in "double Diabetes"
|
| Acronym: |
TOLEDDO
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Double Diabetes
|
| Interventions: |
DRUG: Insulin + semaglutide treatment|DRUG: Usual insulin treatment|BIOLOGICAL: Biological check-up
|
| Outcome Measures: |
Primary: Percentage of time spent within glycemic target range (0.70-1.80 g/l), Change from baseline at Day 180 |
|
| Sponsor/Collaborators: |
Sponsor: Centre Hospitalier Universitaire Dijon
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
76
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-07-12
|
| Completion Date: |
2026-08
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-20
|
| Locations: |
Chu Dijon Bourgogne, Dijon, 21000, France
|
| URL: |
https://clinicaltrials.gov/show/NCT05305794
|
